Methylation markers in prostate biopsies are prognosticators for late biochemical recurrence and therapy after surgery in prostate cancer patients

After diagnosis of prostate cancer is confirmed by a positive biopsy, the tumor may be surgically removed via radical prostatectomy (RP). However, many prostate cancer patients experience biochemical recurrence post-surgery and/or undergo salvage radiotherapy or hormone therapy. Timely treatment is required to prevent the spread of disease in these cases, and biopsy tissue may hold potential for disease prognostication before surgery is ever performed. We previously developed a prognostic multi-gene methylation panel in RP specimens, including APC, CRIP3, HOXD3, and TGFB2.

Source: Journal of Molecular Diagnostics - October 8, 2019 Category: Pathology Authors: Andrea J. Savio, Shivani Kamdar, Renu Jeyapala, Ekaterina Olkhov-Mitsel, Carmelle Cuizon, Antonio Finelli, Alexandre R. Zlotta, Ants Toi, Neil E. Fleshner, Theodorus van der Kwast, Bharati Bapat Tags: Regular Article Source Type: research